An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.There was no additional patient information provided.This report is being filed on an international product, list number 7c18 that has a similar product distributed in the us, list number 1l82.
|
A review of tickets found only one additional ticket for false reactive anti-hbs results for lot 01345fn00.A review of the trending report determined that there are no trends for the issue for the lot.Return testing was not completed as returns were not available.Historical performance in the field of architect anti-hbs reagent lots using world wide data through abbottlink was evaluated.The patient median result for lot 01345fn00 was comparable with all other lots in the field and confirms no systemic issue for the lot.A review of the manufacturing documentation did not identify any issues associated with the customer's observation.Labeling was reviewed which adequately addresses the current issue.The product labeling states that for diagnostic purposes, results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute, chronic, or recovered infection.It is possible that the potential falsely elevated results are due to reactivity following transfusion.Based on the investigation no product deficiency was identified for the architect anti-hbs reagent, lot 01345fn00.
|